{"id":"https://openalex.org/W2113058482","doi":"https://doi.org/10.1158/1535-7163.mct-14-0923-t","title":"Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus","display_name":"Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus","publication_year":2015,"publication_date":"2015-02-19","ids":{"openalex":"https://openalex.org/W2113058482","doi":"https://doi.org/10.1158/1535-7163.mct-14-0923-t","mag":"2113058482","pmid":"https://pubmed.ncbi.nlm.nih.gov/25695956"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-14-0923-t","doi":"https://doi.org/10.1158/1535-7163.mct-14-0923-t","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-14-0923-t","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037380551","display_name":"Yingmiao Liu","orcid":"https://orcid.org/0000-0003-3516-5844","observed_orcids":["https://orcid.org/0000-0003-3516-5844"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yingmiao Liu","raw_affiliation_strings":["1Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4210126298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062010101","display_name":"Mark D. Starr","orcid":"https://orcid.org/0009-0003-9664-6235","observed_orcids":["https://orcid.org/0009-0003-9664-6235"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark D. Starr","raw_affiliation_strings":["1Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4210126298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103918869","display_name":"John C. Brady","orcid":"https://orcid.org/0009-0004-7982-1211","observed_orcids":["https://orcid.org/0009-0004-7982-1211"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John C. Brady","raw_affiliation_strings":["1Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4210126298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070264002","display_name":"Christel N. Rushing","orcid":"https://orcid.org/0000-0001-7453-2120","observed_orcids":["https://orcid.org/0000-0001-7453-2120"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christel Rushing","raw_affiliation_strings":["2Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4210126298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043601003","display_name":"Anuradha Bulusu","orcid":"https://orcid.org/0000-0002-0302-5751","observed_orcids":["https://orcid.org/0000-0002-0302-5751"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anuradha Bulusu","raw_affiliation_strings":["2Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4210126298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084337375","display_name":"Herbert Pang","orcid":"https://orcid.org/0000-0002-7896-6716","observed_orcids":["https://orcid.org/0000-0002-7896-6716"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]},{"id":"https://openalex.org/I889458895","display_name":"University of Hong Kong","ror":"https://ror.org/02zhqgq86","country_code":"HK","type":"education","lineage":["https://openalex.org/I889458895"]}],"countries":["HK","US"],"is_corresponding":false,"raw_author_name":"Herbert Pang","raw_affiliation_strings":["2Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina","3School of Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4210126298"]},{"raw_affiliation_string":"3School of Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China","institution_ids":["https://openalex.org/I889458895"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069465431","display_name":"Wanda Honeycutt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wanda Honeycutt","raw_affiliation_strings":["1Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4210126298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003099045","display_name":"Anthony Amara","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anthony Amara","raw_affiliation_strings":["1Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4210126298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012856380","display_name":"Ivy P. Altomare","orcid":"https://orcid.org/0000-0002-1222-885X","observed_orcids":["https://orcid.org/0000-0002-1222-885X"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ivy Altomare","raw_affiliation_strings":["1Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4210126298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000347168","display_name":"Hope Elizabeth Uronis","orcid":"https://orcid.org/0009-0000-1565-1939","observed_orcids":["https://orcid.org/0009-0000-1565-1939"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hope E. Uronis","raw_affiliation_strings":["1Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4210126298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046311492","display_name":"Herbert I. Hurwitz","orcid":"https://orcid.org/0000-0003-3242-9197","observed_orcids":["https://orcid.org/0000-0003-3242-9197"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Herbert I. Hurwitz","raw_affiliation_strings":["1Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4210126298"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5044586794","display_name":"Andrew B. Nixon","orcid":"https://orcid.org/0000-0003-3971-2964","observed_orcids":["https://orcid.org/0000-0003-3971-2964"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew B. Nixon","raw_affiliation_strings":["1Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4210126298"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.7278,"has_fulltext":false,"cited_by_count":24,"citation_normalized_percentile":{"value":0.73933011,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"14","issue":"4","first_page":"1048","last_page":"1056"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11355","display_name":"Inflammatory Biomarkers in Disease Prognosis","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9959999918937683},{"id":"https://openalex.org/keywords/everolimus","display_name":"everolimus","score":1.0},{"id":"https://openalex.org/keywords/plasma-biomarkers","display_name":"plasma biomarkers","score":0.7710000276565552},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.8259999752044678},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9089999794960022},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":1.0},{"id":"https://openalex.org/keywords/c-reactive-protein","display_name":"C-reactive protein","score":0.8289999961853027},{"id":"https://openalex.org/keywords/igfbp-1","display_name":"IGFBP-1","score":0.7789999842643738},{"id":"https://openalex.org/keywords/igfbp-2","display_name":"IGFBP-2","score":0.902999997138977},{"id":"https://openalex.org/keywords/igfbp-3","display_name":"IGFBP-3","score":0.9990000128746033},{"id":"https://openalex.org/keywords/tgf-beta-receptor-iii","display_name":"TGF-beta receptor III","score":0.6790000200271606},{"id":"https://openalex.org/keywords/tissue-factor","display_name":"tissue factor","score":0.8339999914169312},{"id":"https://openalex.org/keywords/icam-1","display_name":"ICAM-1","score":0.9800000190734863},{"id":"https://openalex.org/keywords/thbs2","display_name":"thrombospondin-2","score":0.921999990940094},{"id":"https://openalex.org/keywords/inflammation","display_name":"inflammation","score":0.640999972820282},{"id":"https://openalex.org/keywords/igf-signaling","display_name":"IGF signaling","score":0.996999979019165},{"id":"https://openalex.org/keywords/mtor","display_name":"mTOR","score":0.6759999990463257},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5170000195503235}],"concepts":[{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8311789035797119},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7857906818389893},{"id":"https://openalex.org/C2779699572","wikidata":"https://www.wikidata.org/wiki/Q421052","display_name":"Everolimus","level":2,"score":0.7631938457489014},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6955171823501587},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.6518952250480652},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6330317258834839},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.5898370146751404},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.5787715911865234},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.527937114238739},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4951998293399811},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.45260635018348694},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.24997466802597046},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.17146790027618408},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.13826987147331238},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.07054618000984192},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000068338","descriptor_name":"Everolimus","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D015415","descriptor_name":"Biomarkers","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1158/1535-7163.mct-14-0923-t","doi":"https://doi.org/10.1158/1535-7163.mct-14-0923-t","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-14-0923-t","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:25695956","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25695956","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:hub.hku.hk:10722/212509","doi":null,"is_oa":false,"landing_page_url":"http://hdl.handle.net/10722/212509","pdf_url":null,"source":{"id":"https://openalex.org/S4377196271","display_name":"The HKU Scholars Hub (University of Hong Kong)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I889458895","host_organization_name":"University of Hong Kong","host_organization_lineage":["https://openalex.org/I889458895"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9922999739646912,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":45,"referenced_works":["https://openalex.org/W18437062","https://openalex.org/W1584352251","https://openalex.org/W1964212603","https://openalex.org/W1965626427","https://openalex.org/W1967023901","https://openalex.org/W1971837077","https://openalex.org/W1982585264","https://openalex.org/W1982621240","https://openalex.org/W1985335252","https://openalex.org/W1985458442","https://openalex.org/W2017018900","https://openalex.org/W2035763807","https://openalex.org/W2037834137","https://openalex.org/W2041634395","https://openalex.org/W2043237487","https://openalex.org/W2044580027","https://openalex.org/W2046507292","https://openalex.org/W2049838597","https://openalex.org/W2050753692","https://openalex.org/W2056408500","https://openalex.org/W2080100938","https://openalex.org/W2080274549","https://openalex.org/W2101995865","https://openalex.org/W2102152192","https://openalex.org/W2103188727","https://openalex.org/W2115735904","https://openalex.org/W2115822788","https://openalex.org/W2118677643","https://openalex.org/W2120129511","https://openalex.org/W2125853921","https://openalex.org/W2132378346","https://openalex.org/W2134138119","https://openalex.org/W2134855990","https://openalex.org/W2135400147","https://openalex.org/W2139877124","https://openalex.org/W2145372211","https://openalex.org/W2146412564","https://openalex.org/W2147834058","https://openalex.org/W2157769714","https://openalex.org/W2167761137","https://openalex.org/W2208115725","https://openalex.org/W2596478495","https://openalex.org/W2968909113","https://openalex.org/W3139763557","https://openalex.org/W6684593726"],"related_works":["https://openalex.org/W1985335252","https://openalex.org/W4200493332","https://openalex.org/W2186364980","https://openalex.org/W2077980958","https://openalex.org/W2795491662","https://openalex.org/W2755858865","https://openalex.org/W2142765731","https://openalex.org/W2608179723","https://openalex.org/W3119765737","https://openalex.org/W4311089005"],"abstract_inverted_index":{"A":[0],"novel":[1],"combination":[2],"of":[3,42,89,112,142,196],"bevacizumab":[4,83,170],"and":[5,36,49,58,84,96,104,115,120,128,133,145,156,171,179,191],"everolimus":[6,85],"was":[7],"evaluated":[8],"in":[9,14,77,167],"refractory":[10],"colorectal":[11],"cancer":[12],"patients":[13,27],"a":[15],"phase":[16],"II":[17],"trial.":[18],"In":[19],"this":[20],"retrospective":[21],"analysis,":[22],"plasma":[23],"samples":[24],"from":[25],"49":[26],"were":[28,52,70,80,124,164],"tested":[29],"for":[30,126,139],"over":[31],"40":[32],"biomarkers":[33,163],"at":[34,47,151],"baseline":[35,48,137],"after":[37],"one":[38],"or":[39],"two":[40],"cycles":[41],"drug":[43],"administration.":[44],"Analyte":[45],"levels":[46,88],"change":[50],"on-treatment":[51,149],"correlated":[53,93,117,175],"with":[54,94,118,176,189],"progression-free":[55],"survival":[56,60],"(PFS)":[57],"overall":[59],"(OS)":[61],"using":[62,72],"univariate":[63],"Cox":[64,73],"proportional":[65],"hazard":[66],"modeling.":[67,74],"Multivariable":[68],"analyses":[69],"conducted":[71],"Significant":[75],"changes":[76,111],"multiple":[78,162],"markers":[79,91,174,183],"observed":[81],"following":[82],"treatment.":[86],"Baseline":[87],"six":[90],"significantly":[92,165],"PFS":[95,119,129,178],"OS,":[97],"including":[98],"CRP,":[99,143],"Gro-\u03b1,":[100,144],"IGFBP-1,":[101],"TF,":[102,146],"ICAM-1,":[103],"TSP-2":[105],"(P":[106,130],"<":[107],"0.05).":[108],"At":[109],"C2D1,":[110],"IGFBP-3,":[113,155],"TGF\u03b2-R3,":[114],"IGFBP-2":[116],"OS.":[121,180],"Prognostic":[122],"models":[123],"developed":[125],"OS":[127,140],"=":[131],"0.0002":[132],"0.004,":[134],"respectively).":[135],"The":[136],"model":[138,150],"consisted":[141],"while":[147],"the":[148],"C2D1":[152],"included":[153],"IGFBP-2,":[154],"TGF\u03b2-R3.":[157],"These":[158],"data":[159],"demonstrated":[160],"that":[161],"modulated":[166],"response":[168],"to":[169,186],"everolimus.":[172],"Several":[173],"both":[177],"Interestingly,":[181],"these":[182],"are":[184],"known":[185],"be":[187],"associated":[188],"inflammation":[190],"IGF":[192],"signaling,":[193],"key":[194],"modulators":[195],"mTOR":[197],"biology.":[198]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":3},{"year":2014,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}